Focus

Sjön Therapeutics is involved in development, ownership (by patents), production, and licensing of recombinant adeno-associated virus gene constructs (serotype aav2 and various hybrids) for clinical trials and treatment in the field of human gene therapy. We also offer worldwide human genome sequencing service for screening of disease biomarkers, and certain research and custom order products (see below). The product portfolio addresses the following human conditions: Lung Cancer [raav2.5p130, raav2.5e1a], Liver Cancer [raav2.3p130, raav2.3e1a], Insulin resistant (type 2) diabetes [raav2acrp30], HIV/AIDS (integrase inhibitor)[raav2;2,5-dkgr], and aav based HIV/AIDS cocktails depending on results of nucleic acid based HIV-1 viral load assay kit (see research below) in early stage, middle stage, and late stage HIV/AIDS. Please note: For clinical trials and treatment, if not enough virus is used, it will not give 100% of infection. If too much virus is used, it will cause cytotoxicity or other undesired effects. You should use the minimal virus concentration that will give 100% gene delivery. This optimal concentration differs dramatically between cell types. To determine this optimal concentration of virus, you could conduct pilot testing in your system by using marker adenoviruses. For most cell types, viral concentrations of 2 x 10^5 - 1 x 10^6 IFU/PFU (infectious unit)/ml of media gives 100% of infection wthout visible side effects. However, I recommend you test your cell system by using marker viruses. Exclusive licensing of intellectual property (patents) is available through 'Survivant Consulting LLC' at a cost equivalent to US $210,000 per construct. A viral biosensor is planned. For further inquiries (customers, physicians, hospitals, healthcare providers) please email sdoddi11@hotmail.com or call +91-9773033833 (leave message). Thank you - Mr. Somesh R. Doddi, Chief Scientist & CEO